Hamptons Homebuildi...
Health Care: Drugs
Vivus (VVUS: NASDAQ)
$14.82 0.32 | 2.21%
05/24/13 - 04:00 PM ET
3.72M / 2.55M
Vol / Avg. Vol:14.42 / 14.50
Open / Prev. Close:14.33 - 15.36
Today's Range:9.86 - 31.21
52 Wk Range:8.05%
Performance YTD:TheStreet Rating:
Portfolios with VVUS
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserMy Watch List
- ContributorStocks Rising On Unusual Vo...
- User2012 picks 10/28/20121
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- UserMy Watch
Latest VVUS Headlines from TheStreet
- Bullish Two Hundred Day Moving Average Cross - VVUS 05.23.13 | 04:05 pm
- VIVUS Announces Scientific Presentations 05.22.13 | 07:05 am
- VIVUS Announces Pricing Of Offering Of $220 Million Of 4.50% Convertible Senior Notes 05.16.13 | 07:05 am
- VIVUS Announces Proposed Offering Of Convertible Senior Notes 05.15.13 | 07:05 am
- VIVUS Announces Scientific Presentations 05.14.13 | 07:05 am
- VIVUS Mails Letter To Stockholders Providing Business Update 05.13.13 | 07:05 am
- VIVUS Appoints J. Martin Carroll And Jorge Plutzky, M.D. To Board Of Directors 05.13.13 | 07:05 am
- 4 Stocks Spiking on Big Volume 05.08.13 | 09:05 pm
- VIVUS Reports First Quarter 2013 Financial Results 05.08.13 | 07:05 am
- Happy Day for Arena Bulls, Bears As Belviq Launch Finally Arrives 05.07.13 | 11:05 am
Press Releases for VVUS
- VIVUS Announces FDA Approval Of Qsymia REMS Modification Allowing Access Through Certified Retail Pharmacies - PR Newswire 04.16.13 | 02:04 pm
- New Obesity Education Program To Premiere At American College Of Physicians (ACP) Annual Meeting - PR Newswire 04.10.13 | 10:04 am
- Analysis In Health Economics Review Concludes Effective Medical Obesity Treatment Could Reduce Medicare Spending - PR Newswire 03.25.13 | 06:03 am
- VIVUS Launches Mobile App To Help Patients Lose Weight - PR Newswire 03.07.13 | 07:03 am
- VIVUS Announces New Qsymia Offer - PR Newswire 03.05.13 | 07:03 am
- Study Concludes That Weight Loss With Qsymiaâ¿¢ Significantly Improves Multiple Cardiovascular Disease Risk Factors - PR Newswire 02.01.13 | 07:02 am
- VIVUS Announces Express Scripts Adds Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV To Its Standard Benefits Program - PR Newswire 12.20.12 | 06:12 am
- Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules - PR Newswire 11.12.12 | 07:11 am
- VIVUS Submits REMS Amendment To FDA For Qsymia (Phentermine And Topiramate Extended-Release) Capsules CIV - PR Newswire 10.17.12 | 07:10 am
- Express Scripts Joins Qsymia⢠(Phentermine And Topiramate Extended-Release) Certified Home Delivery Pharmacy Network - PR Newswire 10.08.12 | 07:10 am
Partner Headlines for VVUS
- A Look At 3 Obesity Stocks - Seeking Alpha 03.05.13 | 09:03 am
- UPDATE: JP Morgan Cuts PT to $22 on VIVUS Following Q4 Report - Benzinga 02.26.13 | 09:02 am
- Arena's Recent Outperform Call And A Probability Weighted Valuation - Seeking Alpha 02.08.13 | 08:02 am
- Novo Nordisk Earnings Beat Views; Competition Looms - Investor's Business Daily 01.31.13 | 04:01 pm
- Orexigen: The Best Bet In Obesity For 2013 - Seeking Alpha 12.17.12 | 09:12 am
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Vivus Reports A Weak 1st Quarter For Qsymia - Seeking Alpha 11.08.12 | 09:11 am
- Vivus Reports Earnings And Initial Results Of Qsymia Sales - Seeking Alpha 11.06.12 | 09:11 am
- Vivus Gets Expected European Rejection - Seeking Alpha 10.19.12 | 09:10 am
- The right data is key to spotting trends - NASDAQ 09.21.12 | 02:09 pm
